[go: up one dir, main page]

Jing et al., 2021 - Google Patents

ACE2‐based decoy receptors for SARS coronavirus 2

Jing et al., 2021

View PDF
Document ID
5210219328366383200
Author
Jing W
Procko E
Publication year
Publication venue
Proteins: Structure, Function, and Bioinformatics

External Links

Snippet

SARS coronavirus 2 is neutralized by proteins that block receptor‐binding sites on spikes that project from the viral envelope. In particular, substantial research investment has advanced monoclonal antibody therapies to the clinic where they have shown partial …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Similar Documents

Publication Publication Date Title
Jing et al. ACE2‐based decoy receptors for SARS coronavirus 2
Larue et al. Rationally designed ACE2-derived peptides inhibit SARS-CoV-2
Martinez-Flores et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants
Westendorf et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Duan et al. The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens
Zhao et al. Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability
Xiu et al. Inhibitors of SARS-CoV-2 entry: current and future opportunities
Ricke Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies
Ilinykh et al. Non-neutralizing antibodies from a Marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies
Zhang et al. Advances in developing ACE2 derivatives against SARS-CoV-2
Arimori et al. Engineering ACE2 decoy receptors to combat viral escapability
Gilchuk et al. Pan-ebolavirus protective therapy by two multifunctional human antibodies
Verma et al. A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics
Park et al. Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses
WO2021170131A1 (en) Soluble ace2 and fusion protein, and applications thereof
Tortorici et al. Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody
Adams et al. Structural and functional basis of VLDLR usage by Eastern equine encephalitis virus
Kovacech et al. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern
Sheikhi et al. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein
KR20230141853A (en) Sabecovirus binding agent
Wines et al. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Yu et al. Protective efficacy of novel engineered human Ace2-FC fusion protein against Pan-SARS-Cov-2 infection in vitro and in vivo
Svilenov et al. Efficient inhibition of SARS-CoV-2 strains by a novel ACE2-IgG4-Fc fusion protein with a stabilized hinge region
Suryadevara et al. Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV
Dërmaku-Sopjani et al. Interactions between ACE2 and SARS-CoV-2 S protein: Peptide inhibitors for potential drug developments against COVID-19